Several treatment regimens that specifically target pro-angiogenic factors (such as VEGF, VEGFR and PDGFR) have been approved by the FDA for the treatment of advanced ccRCC. This evidence concerns the gene PDGFRB and nonpapillary renal cell carcinoma.